<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acute bacterial rhinosinusitis in children: Microbiology and management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acute bacterial rhinosinusitis in children: Microbiology and management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acute bacterial rhinosinusitis in children: Microbiology and management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ellen R Wald, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheldon L Kaplan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Glenn C Isaacson, MD, FAAP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert A Wood, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 10, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute rhinosinusitis is a disease that results from infection of one or more of the paranasal sinuses. A viral infection associated with the common cold is the most frequent etiology of acute rhinosinusitis, more properly called viral rhinosinusitis. Acute bacterial rhinosinusitis (ABRS) occurs when there is secondary bacterial infection of the sinuses. The clinical course (ie, duration, severity, and improvement or worsening of symptoms  (
         <a class="graphic graphic_table graphicRef103739" href="/z/d/graphic/103739.html" rel="external">
          table 1
         </a>
         )) distinguishes uncomplicated viral rhinosinusitis from ABRS  (
         <a class="graphic graphic_table graphicRef83921" href="/z/d/graphic/83921.html" rel="external">
          table 2
         </a>
         ), a distinction that is necessary to prevent unnecessary use of antibiotics. (See
         <a class="medical medical_review" href="/z/d/html/6069.html" rel="external">
          "Acute bacterial rhinosinusitis in children: Clinical features and diagnosis", section on 'Acute bacterial rhinosinusitis'
         </a>
         .)
        </p>
        <p>
         The microbiology and treatment of ABRS in children will be discussed here. The clinical features and diagnosis of ABRS in children and acute sinusitis and rhinosinusitis in adults are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6069.html" rel="external">
          "Acute bacterial rhinosinusitis in children: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6871.html" rel="external">
          "Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83012.html" rel="external">
          "Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment"
         </a>
         .)
        </p>
        <p>
         Our approach to the management of ABRS in children is generally consistent with recommendations of the American Academy of Pediatrics and the Infectious Diseases Society of America. (See
         <a class="local">
          'Society guideline links'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          MICROBIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H704286561">
         <span class="h2">
          Common pathogens
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Uncomplicated ABRS
         </strong>
         <em>
          – Haemophilus influenzae
         </em>
         (nontypeable),
         <em>
          Streptococcus pneumoniae
         </em>
         , and
         <em>
          Moraxella catarrhalis
         </em>
         are the predominant causes of uncomplicated ABRS [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cultures of middle ear fluid obtained by tympanocentesis from children with acute otitis media (AOM) are used as a surrogate for cultures of the paranasal sinuses because AOM and ABRS have similar pathogenesis and microbiology [
         <a href="#rid3">
          3,4
         </a>
         ]. Although culture of material aspirated from the sinus yielding ≥10
         <sup>
          4
         </sup>
         colony-forming units/mL of bacteria is the standard for determining the etiology of ABRS [
         <a href="#rid5">
          5
         </a>
         ], sinus aspiration is an invasive procedure that is not routinely performed in children with uncomplicated ABRS. The use of middle ear cultures as a surrogate for cultures of the paranasal sinuses has been validated by studies of sinus aspirates obtained from children with uncomplicated ABRS that were performed before and after the widespread development of antibiotic-resistant
         <em>
          S. pneumoniae
         </em>
         and the routine use of vaccines against
         <em>
          S. pneumoniae
         </em>
         [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Limited data detailing the microbiology of AOM in the post-13-valent pneumococcal conjugate vaccine (
         <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">
          PCV13
         </a>
         ) era highlight the prominence of nontypeable
         <em>
          H. influenzae
         </em>
         , including beta-lactamase positive isolates [
         <a href="#rid8">
          8-12
         </a>
         ]. In 2017, it was estimated that
         <em>
          H. influenzae
         </em>
         accounted for approximately 50 to 60 percent of middle ear isolates in AOM,
         <em>
          S. pneumoniae
         </em>
         for 15 to 25 percent, and
         <em>
          M. catarrhalis
         </em>
         for 12 to 15 percent [
         <a href="#rid11">
          11,13-16
         </a>
         ]. The presumption that isolates recovered from children with uncomplicated ABRS would be similar was confirmed in a study of 31 children with severe symptoms of acute maxillary sinusitis who underwent sinus aspiration [
         <a href="#rid7">
          7
         </a>
         ]. The most common bacteria recovered were
         <em>
          H. influenzae
         </em>
         (45 percent),
         <em>
          S. pneumoniae
         </em>
         (32 percent), and
         <em>
          M. catarrhalis
         </em>
         (16 percent). (See
         <a class="medical medical_review" href="/z/d/html/6021.html" rel="external">
          "Acute otitis media in children: Epidemiology, microbiology, and complications", section on 'Microbiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Several studies have reported isolation of
         <em>
          Staphylococcus aureus
         </em>
         from sinus aspirates (obtained endoscopically) or from cultures of the middle meatus in children (most of whom had chronic sinusitis) [
         <a href="#rid17">
          17-19
         </a>
         ]. However, these studies must be interpreted with caution because of methodologic limitations (eg, unknown indication for obtaining culture, lack of quantification, possibility of contamination from the nasal cavity) and because cultures of the middle meatus have not been established as a reliable surrogate for maxillary sinus aspirates in children [
         <a href="#rid20">
          20
         </a>
         ]. Nonetheless,
         <em>
          S. aureus,
         </em>
         including methicillin-resistant
         <em>
          S. aureus
         </em>
         , has been recovered from cultures in patients with orbital cellulitis and epidural abscess, presumably complications of ABRS [
         <a href="#rid21">
          21-23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications of ABRS
         </strong>
         – The microbiology of the complications of ABRS differs from that of uncomplicated ABRS. In retrospective studies of the microbiology of complicated ABRS in children, polymicrobial infections were common and
         <em>
          Streptococcus
         </em>
         species (eg,
         <em>
          Streptococcus anginosus
         </em>
         group), other anaerobes, and
         <em>
          Staphylococcus
         </em>
         species were more frequently isolated than
         <em>
          H. influenzae
         </em>
         ,
         <em>
          S. pneumoniae
         </em>
         , and
         <em>
          M. catarrhalis
         </em>
         [
         <a href="#rid24">
          24-30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H704286587">
         <span class="h2">
          Antimicrobial susceptibility
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          S. pneumoniae
         </em>
         – The proportion of isolates of
         <em>
          S. pneumoniae
         </em>
         that are nonsusceptible to penicillin varies from community to community. Although the incidence of AOM caused by penicillin-resistant
         <em>
          S. pneumoniae
         </em>
         decreased for several years after
         <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">
          PCV13
         </a>
         replaced the 7-valent pneumococcal conjugate vaccine in 2010 [
         <a href="#rid13">
          13
         </a>
         ], cultures from tympanocenteses performed during 2015 to 2019 show an increase in serotypes not included in PCV13 (eg, 35B, 15B/C, and 23B) [
         <a href="#rid12">
          12
         </a>
         ]. Children unimmunized or underimmunized with PCV are more likely to have resistant strains [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          H. influenzae
         </em>
         – Between 30 to 50 percent of
         <em>
          H. influenzae
         </em>
         [
         <a href="#rid13">
          13
         </a>
         ] are likely to be beta-lactamase positive and nonsusceptible to
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         . In a single center longitudinal study of AOM pathogens between 2015 and 2019, nearly 49 percent of the
         <em>
          H. influenzae
         </em>
         isolates were beta-lactamase producing [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          M. catarrhalis
         </em>
         – Close to 100 percent of
         <em>
          M. catarrhalis
         </em>
         are likely to be beta-lactamase positive and nonsusceptible to
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H512799123">
         <span class="h2">
          Risk factors for antimicrobial resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risks factors for resistant
         <em>
          S. pneumoniae
         </em>
         and
         <em>
          H. influenzae
         </em>
         include [
         <a href="#rid31">
          31-37
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Living in an area with high endemic rates (ie, ≥10 percent) of invasive penicillin-nonsusceptible
         <em>
          S. pneumoniae
         </em>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age &lt;2 years
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Daycare attendance
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antibiotic therapy within the month before presentation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hospitalization within the past five days
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unimmunized or underimmunized with PCV (see
         <a class="medical medical_review" href="/z/d/html/6053.html" rel="external">
          "Pneumococcal vaccination in children", section on 'Routine immunization for children &lt;5 years'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2026429134">
         <span class="h1">
          WHEN TO INITIATE ANTIBIOTICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prompt initiation of antibiotics is necessary for children with ABRS and complications or suspected complications  (
         <a class="graphic graphic_table graphicRef83408" href="/z/d/graphic/83408.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/6069.html" rel="external">
          "Acute bacterial rhinosinusitis in children: Clinical features and diagnosis", section on 'Complications'
         </a>
         and
         <a class="local">
          'Complicated ABRS'
         </a>
         below.)
        </p>
        <p>
         There are three clinical presentations of acute bacterial sinusitis  (
         <a class="graphic graphic_table graphicRef103739" href="/z/d/graphic/103739.html" rel="external">
          table 1
         </a>
         ). For children with ABRS and 10 days of symptoms that are neither severe nor worsening, and none of the indications for immediate antimicrobial therapy listed below, we either provide immediate antimicrobial therapy or a three-day period of observation, depending upon patient and caregiver preference. Additional factors that are considered in this decision include severity of symptoms, quality of life, past history of ABRS, cost and ease of administration of antibiotics, and concerns about adverse effects of antibiotics or development of complications. Immediate treatment with antibiotics is preferred to observation because although ABRS may resolve without antibiotics, resolution of symptoms usually occurs earlier and is more likely with than without antibiotics.
        </p>
        <p>
         We initiate antimicrobial therapy
         <strong>
          at the time of presentation
         </strong>
         to medical attention for children with ABRS and one or more of the following [
         <a href="#rid38">
          38
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A clinical presentation of severe symptoms or worsening symptoms  (
         <a class="graphic graphic_table graphicRef103739" href="/z/d/graphic/103739.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Receipt of antibiotic therapy in the previous four weeks
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concurrent bacterial infection (eg, pneumonia, suppurative cervical adenitis, group A streptococcal pharyngitis, acute otitis media)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Certain underlying conditions, including asthma, cystic fibrosis, immunodeficiency, previous sinus surgery, or anatomic abnormalities of the upper respiratory tract
        </p>
        <p>
        </p>
        <p>
         Randomized trials evaluating antibiotics versus placebo for the treatment of ABRS in children have conflicting results [
         <a href="#rid39">
          39-42
         </a>
         ]. In a meta-analysis of four trials including a total of 382 children [
         <a href="#rid43">
          43
         </a>
         ], the rate of improvement or clinical cure was greater among children treated with antibiotics than with placebo (odds ratio [OR] 2.0, 95% CI 1.2-3.5). However, various limitations of these trials diminish confidence in the conclusions. In a subsequent blinded trial that included nasopharyngeal (NP) swab culture, 510 children ages 2 to 12 years were randomly assigned to receive 10 days of
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         or 10 days of placebo [
         <a href="#rid44">
          44
         </a>
         ]. The reduction in symptom burden score was greater in the amoxicillin-clavulanate group than in the placebo group, and the failure rate (based on an increase in symptoms or inadequate resolution of symptoms) was lower in the amoxicillin-clavulanate group compared with placebo (30 percent versus 43 percent, OR 0.69, 95% CI 0.54-0.88). However, there was no difference in symptom burden score reduction among the subset whose baseline cultures did not detect a pathogen. Until rapid testing for NP pathogens is available, shared decision-making with the family about antibiotic treatment is appropriate. The options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Empiric treatment without testing
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Empiric treatment after testing with plan to discontinue if negative
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testing with treatment only if test is positive
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Watchful waiting with treatment if symptoms persist beyond three days
        </p>
        <p>
        </p>
        <p>
         There have been no randomized, placebo-controlled trials of antibiotic treatment for ABRS that have used pre- and posttreatment quantitative sinus aspirate culture as the standard for diagnosis and cure. Studies that use clinical and/or radiologic criteria for diagnosis and outcome may underestimate the benefit of antibiotic therapy because they are likely to include at least some patients with self-limited uncomplicated viral upper respiratory tract infection.
        </p>
        <p class="headingAnchor" id="H2530907758">
         <span class="h1">
          OUTPATIENT MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         We generally treat children with ABRS who are well-appearing and without complications or suspected complications  (
         <a class="graphic graphic_table graphicRef83408" href="/z/d/graphic/83408.html" rel="external">
          table 3
         </a>
         ) as outpatients  (
         <a class="graphic graphic_algorithm graphicRef135260 graphicRef135256" href="/z/d/graphic/135260.html" rel="external">
          algorithm 1A-B
         </a>
         ). Patients older than one year with mild preseptal cellulitis (characterized by slight swelling about the eye such that the eye is open more than 50 percent) and no signs of toxicity may be treated as outpatients provided that follow-up the next day is ensured. (See
         <a class="local">
          'Indications for hospitalization'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/16650.html" rel="external">
          "Preseptal cellulitis", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H742622640">
         <span class="h2">
          Indications for referral
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with uncomplicated ABRS can usually be managed by their primary care provider. Indications for consultation with a specialist (eg, infectious disease, otolaryngology, immunology) include [
         <a href="#rid32">
          32,45,46
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Need for sinus aspiration (see
         <a class="medical medical_review" href="/z/d/html/6069.html" rel="external">
          "Acute bacterial rhinosinusitis in children: Clinical features and diagnosis", section on 'Microbiologic evaluation'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isolation of resistant or rare pathogens from sinus aspirate (if performed)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diagnosed or suspected immunodeficiency
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent ABRS, particularly if it exacerbates underlying pulmonary conditions (eg, asthma)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3526500914">
         <span class="h2">
          Empiric antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibiotics that are used to treat ABRS must provide antibacterial activity against
         <em>
          S. pneumoniae
         </em>
         ,
         <em>
          H. influenzae
         </em>
         , and
         <em>
          M. catarrhalis
         </em>
         . (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
         Additional factors in the choice of therapy include the severity of illness, risk of complications, likelihood of infection with a resistant organism, adverse drug reactions, acceptability, dosing convenience, and adverse effects  (
         <a class="graphic graphic_algorithm graphicRef135260 graphicRef135256" href="/z/d/graphic/135260.html" rel="external">
          algorithm 1A-B
         </a>
         ) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H656458098">
         <span class="h3">
          Mild/moderate ABRS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mild/moderate ABRS is characterized by a clinical severity score &lt;8  (
         <a class="graphic graphic_table graphicRef83453" href="/z/d/graphic/83453.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No risk factors for antibiotic resistance
         </strong>
         – For children with uncomplicated mild/moderate ABRS who have no risks for antibiotic resistance  (
         <a class="graphic graphic_table graphicRef122110" href="/z/d/graphic/122110.html" rel="external">
          table 5
         </a>
         ), we suggest empiric antimicrobial therapy with standard dose
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         rather than high-dose amoxicillin-clavulanate or other oral antibiotics (eg,
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         , fluoroquinolones, macrolides, or second- or third-generation cephalosporins)  (
         <a class="graphic graphic_algorithm graphicRef135260" href="/z/d/graphic/135260.html" rel="external">
          algorithm 1A
         </a>
         and
         <a class="graphic graphic_table graphicRef83454" href="/z/d/graphic/83454.html" rel="external">
          table 6
         </a>
         ) (see
         <a class="local">
          'Risk factors for antimicrobial resistance'
         </a>
         above) [
         <a href="#rid32">
          32
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          Amoxicillin-clavulanate
         </a>
         45 mg/kg per day of the
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         component orally in two divided doses (maximum daily dose 1.75 g) for 10 days; in the United States, the 200 or 400 mg amoxicillin/5 mL suspension or the 200 or 400 mg chewable tablet can be used for the appropriate clavulanate ratio.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors for antibiotic resistance
         </strong>
         – For children with uncomplicated mild/moderate ABRS who have one or more risks for antibiotic resistance or whose risk factors for antibiotic resistance are unknown  (
         <a class="graphic graphic_table graphicRef122110" href="/z/d/graphic/122110.html" rel="external">
          table 5
         </a>
         ), we suggest treatment with high-dose rather than standard-dose
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef135260" href="/z/d/graphic/135260.html" rel="external">
          algorithm 1A
         </a>
         and
         <a class="graphic graphic_table graphicRef83454" href="/z/d/graphic/83454.html" rel="external">
          table 6
         </a>
         ) (see
         <a class="local">
          'Risk factors for antimicrobial resistance'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          Amoxicillin-clavulanate
         </a>
         90 mg/kg per day of the
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         component orally in two divided doses (maximum daily dose 4 g) for 10 days; in the United States, the 600 mg amoxicillin/5 mL suspension or the 1000 mg extended-release tablet can be used for the appropriate clavulanate ratio.
        </p>
        <p>
        </p>
        <p>
         We prefer
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         for the treatment of ABRS in children because of its spectrum of activity, effectiveness, and safety [
         <a href="#rid13">
          13,32,40,47
         </a>
         ]. The clavulanate component provides better activity than
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         against ampicillin-resistant
         <em>
          H. influenzae
         </em>
         and
         <em>
          M. catarrhalis
         </em>
         . Beta-lactamase producing nontypeable
         <em>
          H. influenzae
         </em>
         is an increasingly important cause of respiratory tract infection in the post-13-valent pneumococcal conjugate vaccine (
         <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">
          PCV13
         </a>
         ) era [
         <a href="#rid13">
          13,32,48-52
         </a>
         ].
        </p>
        <p>
         Other experts suggest
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         for initial therapy of mild/moderate disease [
         <a href="#rid38">
          38
         </a>
         ]. They recommend amoxicillin 45 mg/kg per day orally divided in two doses for children without risk factors for antimicrobial resistance and amoxicillin 90 mg/kg per day orally divided in two doses for children with risk factors for antimicrobial resistance. (See
         <a class="local">
          'Risk factors for antimicrobial resistance'
         </a>
         above.)
        </p>
        <p>
         In a retrospective cohort study of almost 200,000 children and adolescents aged ≤17 years with sinusitis, there was no association between the addition of clavulanate to
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         and treatment failure rate (1.7 percent with clavulanate versus 1.8 percent without [difference -0.03 percent, 95% CI -0.15 to 0.08]) [
         <a href="#rid53">
          53
         </a>
         ]. However, multiple limitations of the study diminish the conclusions that can be drawn.
        </p>
        <p>
         High-dose
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         provides better activity against penicillin-nonsusceptible
         <em>
          S. pneumoniae
         </em>
         and ampicillin-resistant nonbeta-lactamase producing
         <em>
          H. influenzae
         </em>
         than standard-dose amoxicillin-clavulanate [
         <a href="#rid32">
          32,49
         </a>
         ]. However, because of the slight increase in cost and side effects and the stable proportion of penicillin-resistant
         <em>
          S. pneumoniae
         </em>
         in the post-pneumococcal conjugate vaccine era, we suggest that high-dose amoxicillin-clavulanate be reserved for children with severe disease or increased or unknown risk of antibiotic resistance (either penicillin-nonsusceptible
         <em>
          S. pneumoniae
         </em>
         or beta-lactamase producing ampicillin-resistant
         <em>
          H. influenzae
         </em>
         ) [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="local">
          'Risk factors for antimicrobial resistance'
         </a>
         above.)
        </p>
        <p>
         In a meta-analysis of randomized trials, fluoroquinolones provided no advantage over beta-lactam antibiotics in the treatment of ABRS in adults [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H656458106">
         <span class="h3">
          Severe ABRS or risk for severe ABRS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe disease is characterized by a clinical severity score ≥8  (
         <a class="graphic graphic_table graphicRef83453" href="/z/d/graphic/83453.html" rel="external">
          table 4
         </a>
         ). Children with immune-compromising conditions (eg, human immunodeficiency virus [HIV]) are at increased risk for severe disease [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         For children with severe ABRS or risk for severe ABRS who are treated as outpatients, we suggest treatment with high-dose
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         rather than standard-dose amoxicillin-clavulanate or other oral antibiotics  (
         <a class="graphic graphic_algorithm graphicRef135260" href="/z/d/graphic/135260.html" rel="external">
          algorithm 1A
         </a>
         and
         <a class="graphic graphic_table graphicRef83454" href="/z/d/graphic/83454.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          Amoxicillin-clavulanate
         </a>
         90 mg/kg per day of the
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         component orally in two divided doses (maximum daily dose 4 g) for 10 days; in the United States, use the 600 mg amoxicillin/5 mL suspension or the 1000 mg extended-release tablet for the appropriate clavulanate ratio.
        </p>
        <p>
        </p>
        <p>
         We suggest high-dose rather than standard-dose
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         for children with severe ABRS or risk of severe ABRS to provide better activity against penicillin-nonsusceptible
         <em>
          S. pneumoniae
         </em>
         and ampicillin-resistant nonbeta-lactamase producing
         <em>
          H. influenzae
         </em>
         [
         <a href="#rid32">
          32,49
         </a>
         ]. (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
         Alternative single-agent regimens, which have a slightly narrower spectrum of activity than
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         , include a third generation cephalosporin (eg,
         <a class="drug drug_pediatric" data-topicid="13132" href="/z/d/drug information/13132.html" rel="external">
          cefpodoxime
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13125" href="/z/d/drug information/13125.html" rel="external">
          cefdinir
         </a>
         ) or
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          levofloxacin
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef135256" href="/z/d/graphic/135256.html" rel="external">
          algorithm 1B
         </a>
         ) [
         <a href="#rid55">
          55
         </a>
         ]. Suggested doses are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13132" href="/z/d/drug information/13132.html" rel="external">
          Cefpodoxime
         </a>
         10 mg/kg per day orally divided every 12 hours (maximum daily dose 400 mg) for 10 days
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13125" href="/z/d/drug information/13125.html" rel="external">
          Cefdinir
         </a>
         14 mg/kg per day orally divided every 12 or 24 hours (maximum daily dose 600 mg) for 10 days
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          Levofloxacin
         </a>
         10 to 20 mg/kg per day orally divided every 12 to 24 hours (maximum daily dose 500 mg) for 10 days
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13132" href="/z/d/drug information/13132.html" rel="external">
          Cefpodoxime
         </a>
         has greater activity than
         <a class="drug drug_pediatric" data-topicid="13125" href="/z/d/drug information/13125.html" rel="external">
          cefdinir
         </a>
         against
         <em>
          H. influenzae
         </em>
         and is preferred, especially if the patient can take a tablet
         <em>
         </em>
         [
         <a href="#rid56">
          56,57
         </a>
         ]. For the liquid formulation, some clinicians prefer cefdinir because it has a better taste. Although third-generation cephalosporins have been considered inferior to high-dose
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         for penicillin-resistant
         <em>
          S. pneumoniae
         </em>
         , this may be less of an issue if penicillin-resistant
         <em>
          S. pneumoniae
         </em>
         remain less common as a cause of acute otitis media and ABRS following the introduction of
         <a class="drug drug_pediatric" data-topicid="15567" href="/z/d/drug information/15567.html" rel="external">
          PCV13
         </a>
         . (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          Levofloxacin
         </a>
         should be reserved for cases in which there is no other safe and effective alternative (eg, in patients who have anaphylaxis with or are intolerant of beta-lactams) [
         <a href="#rid58">
          58-60
         </a>
         ]. In a meta-analysis of randomized trials, fluoroquinolones provided no advantage over beta-lactam antibiotics in the treatment of ABRS in adults [
         <a href="#rid54">
          54
         </a>
         ]. In addition, fluoroquinolones are associated with more severe side effects than
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         [
         <a href="#rid59">
          59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/490.html" rel="external">
          "Fluoroquinolones", section on 'Children'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          Levofloxacin
         </a>
         typically remains active against multidrug-resistant pneumococci with high-level resistance to penicillin or third-generation cephalosporins and is an option for treatment when patients have failed initial therapy. (See
         <a class="local">
          'Treatment failure in outpatients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H689793379">
         <span class="h3">
          Children with penicillin contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alternatives to
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         for children with contraindications to penicillin depend upon the type of adverse reaction  (
         <a class="graphic graphic_table graphicRef83454" href="/z/d/graphic/83454.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">
          "Penicillin allergy: Immediate reactions"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2087.html" rel="external">
          "Allergy evaluation for immediate penicillin allergy: Skin test-based diagnostic strategies and cross-reactivity with other beta-lactam antibiotics"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children with uncomplicated ABRS who have an immediate reaction (eg, anaphylaxis, bronchospasm) or serious delayed reaction (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis) to penicillin, or a contraindication to cephalosporins, we suggest
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          levofloxacin
         </a>
         10 to 20 mg/kg per day orally divided every 12 or 24 hours [
         <a href="#rid32">
          32,60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/490.html" rel="external">
          "Fluoroquinolones", section on 'Children'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children with uncomplicated ABRS who have a mild delayed hypersensitivity reaction to penicillin antibiotics, we suggest therapy with a third-generation cephalosporin (eg,
         <a class="drug drug_pediatric" data-topicid="13132" href="/z/d/drug information/13132.html" rel="external">
          cefpodoxime
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13125" href="/z/d/drug information/13125.html" rel="external">
          cefdinir
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13132" href="/z/d/drug information/13132.html" rel="external">
          Cefpodoxime
         </a>
         10 mg/kg per day orally divided every 12 hours (maximum daily dose 400 mg),
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13125" href="/z/d/drug information/13125.html" rel="external">
          Cefdinir
         </a>
         14 mg/kg per day orally divided every 12 or 24 hours (maximum daily dose 600 mg)
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13132" href="/z/d/drug information/13132.html" rel="external">
          Cefpodoxime
         </a>
         has greater activity than
         <a class="drug drug_pediatric" data-topicid="13125" href="/z/d/drug information/13125.html" rel="external">
          cefdinir
         </a>
         against
         <em>
          H. influenzae
         </em>
         and is preferred, especially if the patient can take a tablet
         <em>
         </em>
         [
         <a href="#rid56">
          56,57
         </a>
         ]. For the liquid formulation, some clinicians prefer cefdinir because it has a better taste.
        </p>
        <p class="headingAnchor" id="H689793371">
         <span class="h3">
          Children with vomiting
         </span>
         <span class="headingEndMark">
          —
         </span>
         A single dose of
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         50 mg/kg per day (maximum dose 1 g/day) intravenously (IV) or intramuscularly (IM) can be used in children with uncomplicated ABRS and vomiting that precludes administration of oral antibiotics [
         <a href="#rid32">
          32,38
         </a>
         ]. Therapy with an oral antibiotic should be initiated 24 hours later, provided the vomiting has resolved.
        </p>
        <p>
         Vomiting that persists for more than 24 hours and vomiting that is associated with periorbital/orbital swelling and/or persistent headache should prompt consideration of orbital or intracranial complication. Additional evaluation is needed. (See
         <a class="medical medical_review" href="/z/d/html/6069.html" rel="external">
          "Acute bacterial rhinosinusitis in children: Clinical features and diagnosis", section on 'Complications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3298161601">
         <span class="h2">
          Treatment failure in outpatients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment failure is defined by substantial worsening at any time after initiation of antibiotics or failure to improve after three days [
         <a href="#rid39">
          39,40
         </a>
         ]. Treatment failure in children with ABRS who have no evidence of complications  (
         <a class="graphic graphic_table graphicRef83408" href="/z/d/graphic/83408.html" rel="external">
          table 3
         </a>
         ) is often caused by a pathogen resistant to initial antimicrobial therapy [
         <a href="#rid32">
          32,38
         </a>
         ]. (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Consider other causes of symptoms
         </strong>
         – Other causes of treatment failure include a noninfectious cause for symptoms (eg, foreign body, structural abnormality) or ABRS as the initial presentation of immune deficiency [
         <a href="#rid32">
          32,38,61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6069.html" rel="external">
          "Acute bacterial rhinosinusitis in children: Clinical features and diagnosis", section on 'Differential diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5949.html" rel="external">
          "Approach to the child with recurrent infections"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Changes to antibiotic therapy
         </strong>
         – For children with uncomplicated ABRS who are initially treated as outpatients and whose symptoms worsen substantially at any time or fail to improve after three days of initial antimicrobial treatment and in whom other causes of symptoms have been excluded by history or examination, we suggest broadening antimicrobial activity or switching to a different class of antibiotic  (
         <a class="graphic graphic_algorithm graphicRef135260 graphicRef135256" href="/z/d/graphic/135260.html" rel="external">
          algorithm 1A-B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We continue antibiotic therapy for seven days after the child becomes symptom free (ie, a minimum of 10 days) [
         <a href="#rid38">
          38,62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our choices for the new regimen depend upon which antibiotic was used initially:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Initial treatment with standard-dose
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         (standard or high-dose) – We switch to one of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          Amoxicillin-clavulanate
         </a>
         90 mg/kg per day of the
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         component orally in two divided doses (maximum daily dose 4 g); in the United States, the 600 mg amoxicillin/5 mL suspension or the 1000 mg extended-release tablet can be used for the appropriate clavulanate ratio
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          Ceftriaxone
         </a>
         50 mg/kg per day IV or IM (maximum 4 g/day) for one to three days, followed by
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         90 mg/kg per day of the
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         component
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Initial treatment with high-dose
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         – We switch to one of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="13132" href="/z/d/drug information/13132.html" rel="external">
          Cefpodoxime
         </a>
         10 mg/kg per day orally divided every 12 hours (maximum daily dose 400 mg/day)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="13125" href="/z/d/drug information/13125.html" rel="external">
          Cefdinir
         </a>
         14 mg/kg per day orally divided every 12 or 24 hours (maximum daily dose 600 mg/day)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          Levofloxacin
         </a>
         10 to 20 mg/kg per day orally divided every 12 or 24 hours (maximum daily dose 500 mg/day); levofloxacin should be reserved for cases in which there is no other safe and effective alternative [
         <a href="#rid58">
          58-60
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/490.html" rel="external">
          "Fluoroquinolones", section on 'Children'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Initial treatment with
         <a class="drug drug_pediatric" data-topicid="13132" href="/z/d/drug information/13132.html" rel="external">
          cefpodoxime
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13125" href="/z/d/drug information/13125.html" rel="external">
          cefdinir
         </a>
         – We switch to either:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          Amoxicillin-clavulanate
         </a>
         (depending on why a cephalosporin was started) 90 mg/kg per day of the
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         component orally in two divided doses (maximum daily dose 4 g), or
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          Levofloxacin
         </a>
         10 to 20 mg/kg per day orally divided every 12 or 24 hours; levofloxacin should be reserved for cases in which there is no other safe and effective alternative [
         <a href="#rid58">
          58-60
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/490.html" rel="external">
          "Fluoroquinolones", section on 'Children'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Response to second therapy
         </strong>
         – Hospital admission for a trial of intravenous therapy and/or consultation with a specialist (eg, infectious disease, otolaryngology) is warranted for children with ABRS who fail to improve after the second therapy  (
         <a class="graphic graphic_algorithm graphicRef135260 graphicRef135256" href="/z/d/graphic/135260.html" rel="external">
          algorithm 1A-B
         </a>
         ). (See
         <a class="local">
          'Inpatient management'
         </a>
         below and
         <a class="local">
          'Indications for hospitalization'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children with no contraindications to penicillins, we use:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          Ceftriaxone
         </a>
         50 mg/kg per day IV divided every 12 hours (maximum 4 g/day)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children with contraindications to penicillins, we use either:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          Levofloxacin
         </a>
         20 mg/kg per day IV divided every 12 to 24 hours (maximum 500 mg/day), or
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          Meropenem
         </a>
         60 mg/kg per day divided every 8 hours (maximum 3 g/day)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For those who failed treatment with
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          levofloxacin
         </a>
         at 10 mg/kg per day orally, it is reasonable to try levofloxacin at 20 mg/kg per day IV. For those who failed treatment with oral levofloxacin 20 mg/kg per day,
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         is appropriate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, imaging and/or sinus aspiration may be indicated to confirm the diagnosis, evaluate complications, and tailor therapy, particularly for children whose symptoms have not improved or have worsened after three days of initial antibiotics and another three days of the second agent. (See
         <a class="medical medical_review" href="/z/d/html/6069.html" rel="external">
          "Acute bacterial rhinosinusitis in children: Clinical features and diagnosis", section on 'Complicated ABRS'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6069.html" rel="external">
          "Acute bacterial rhinosinusitis in children: Clinical features and diagnosis", section on 'Microbiologic evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H243844183">
         <span class="h2">
          Symptomatic therapy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nasal obstruction/rhinorrhea
         </strong>
         <strong>
          in children without underlying allergic rhinitis –
         </strong>
         For symptomatic management of nasal obstruction and rhinorrhea in children with ABRS who do not have underlying allergic rhinitis, we suggest topical
         <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">
          saline
         </a>
         rather than decongestants, antihistamines, or intranasal glucocorticoids.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although evidence of the efficacy of topical
         <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">
          saline
         </a>
         is limited [
         <a href="#rid63">
          63-65
         </a>
         ], it is unlikely to be harmful or to impede recovery and is inexpensive. Saline nose drops, saline nasal sprays, and/or saline nasal irrigation may help in preventing crust formation and liquefying sinus secretions. In a small randomized trial, nasal saline irrigation improved symptoms, quality-of-life scores, and peak expiratory flow rates in children with acute sinusitis [
         <a href="#rid65">
          65
         </a>
         ]. Additional trials are need to better establish the benefits of topical saline. Nasal irrigants should be prepared from sterile or bottled water; cases of amebic encephalitis associated with nasal irrigation prepared from tap water have been reported [
         <a href="#rid66">
          66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5687.html" rel="external">
          "Free-living amebas and Prototheca", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The benefits of decongestants and antihistamines are unproven [
         <a href="#rid63">
          63,67
         </a>
         ] and they may have adverse effects (eg, impaired sinus drainage, impaired delivery of antibiotics to the nasal mucosa). Although intranasal glucocorticoids theoretically may decrease inflammation of the mucous membranes, which contributes to obstruction of the ostia and impaired mucociliary clearance [
         <a href="#rid68">
          68
         </a>
         ], the benefits demonstrated in randomized trials have been marginal and the trials have methodologic limitations (eg, varying inclusion criteria, inclusion of patients with and without allergies, varying outcome criteria) [
         <a href="#rid38">
          38,69-72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nasal obstruction/rhinorrhea in children with underlying allergic rhinitis
         </strong>
         – Children with ABRS and allergic rhinitis may benefit from antihistamines, decongestants, or intranasal glucocorticoids. The treatment of allergic rhinitis in children is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">
          "Pharmacotherapy of allergic rhinitis", section on 'Approach to specific patient groups'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe headache or facial pain
         </strong>
         — Therapeutic sinus aspiration  (
         <a class="graphic graphic_figure graphicRef101312" href="/z/d/graphic/101312.html" rel="external">
          figure 1
         </a>
         ) may be warranted for relief of severe headache or facial pain [
         <a href="#rid73">
          73
         </a>
         ]. Sinus aspiration should be performed by a specialist. Indications for diagnostic sinus aspiration are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6069.html" rel="external">
          "Acute bacterial rhinosinusitis in children: Clinical features and diagnosis", section on 'Microbiologic evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H742621521">
         <span class="h1">
          INPATIENT MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H1512727261">
         <span class="h2">
          Indications for hospitalization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Indications for hospitalization and parenteral antibiotics in children with ABRS  (
         <a class="graphic graphic_table graphicRef103739" href="/z/d/graphic/103739.html" rel="external">
          table 1
         </a>
         ) include (see
         <a class="local">
          'Inpatient management'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Toxic appearance (eg, lethargic, poorly perfused, cardiorespiratory compromise)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complications or suspected complications  (
         <a class="graphic graphic_table graphicRef83408" href="/z/d/graphic/83408.html" rel="external">
          table 3
         </a>
         ), with the possible exception of preseptal cellulitis (patients older than one year with mild preseptal cellulitis [characterized by slight swelling about the eye such that the eye is open more than 50 percent] and no signs of toxicity may be treated as outpatients provided that follow-up the next day is ensured) (see
         <a class="medical medical_review" href="/z/d/html/6069.html" rel="external">
          "Acute bacterial rhinosinusitis in children: Clinical features and diagnosis", section on 'Complications'
         </a>
         and
         <a class="local">
          'Complicated ABRS'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/16650.html" rel="external">
          "Preseptal cellulitis", section on 'Treatment'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment failure with outpatient therapy (ie, high-dose
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         , third-generation cephalosporin, or
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          levofloxacin
         </a>
         ) (see
         <a class="local">
          'Treatment failure in outpatients'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2935927933">
         <span class="h2">
          Pretreatment evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Consultation with an otolaryngologist for possible sinus aspiration (with Gram stain, aerobic and anaerobic culture, and antimicrobial susceptibility testing) is warranted for children hospitalized with complications of ABRS or failure of outpatient management [
         <a href="#rid32">
          32,73
         </a>
         ]. Isolation of a pathogen and antimicrobial susceptibilities enable better targeting of antimicrobial therapy. (See
         <a class="medical medical_review" href="/z/d/html/6069.html" rel="external">
          "Acute bacterial rhinosinusitis in children: Clinical features and diagnosis", section on 'Microbiologic evaluation'
         </a>
         .)
        </p>
        <p>
         For children who are hospitalized for toxic appearance without complications or suspected complications, sinus aspiration may be deferred pending a trial of intravenous therapy [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         Although there is literature suggesting that endoscopically obtained cultures of the middle meatus may be a surrogate for sinus aspiration, endoscopically obtained cultures of the middle meatus may not reflect the true bacterial etiology in children suspected to have ABRS because the meatus is frequently colonized with
         <em>
          S. pneumoniae
         </em>
         ,
         <em>
          H. influenzae
         </em>
         , and
         <em>
          M. catarrhalis
         </em>
         , even when children are asymptomatic [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4058180180">
         <span class="h2">
          Complicated ABRS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sinus imaging with contrast-enhanced computed tomography (CT) should be performed in patients with symptoms or signs of intracranial or orbital complications  (
         <a class="graphic graphic_table graphicRef83408" href="/z/d/graphic/83408.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/6069.html" rel="external">
          "Acute bacterial rhinosinusitis in children: Clinical features and diagnosis", section on 'Complications'
         </a>
         .)
        </p>
        <p>
         The treatment of complicated sinusitis varies depending upon the complication and is discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preseptal (periorbital) cellulitis (see
         <a class="medical medical_review" href="/z/d/html/16650.html" rel="external">
          "Preseptal cellulitis", section on 'Treatment'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postseptal complications of sinusitis (orbital cellulitis, orbital subperiosteal abscess, orbital abscess) are treated similarly; orbital subperiosteal abscess and orbital abscess may require surgical drainage in addition to antibiotic therapy (see
         <a class="medical medical_review" href="/z/d/html/3414.html" rel="external">
          "Orbital cellulitis", section on 'Treatment'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Septic cavernous sinus thrombosis (see
         <a class="medical medical_review" href="/z/d/html/3410.html" rel="external">
          "Septic dural sinus thrombosis", section on 'Treatment'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Meningitis (see
         <a class="medical medical_review" href="/z/d/html/6010.html" rel="external">
          "Bacterial meningitis in children older than one month: Treatment and prognosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Osteomyelitis of the frontal bone associated with a subperiosteal abscess (Pott puffy tumor) (see
         <a class="medical medical_review" href="/z/d/html/5958.html" rel="external">
          "Hematogenous osteomyelitis in children: Management"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intracranial epidural or subdural abscess (see
         <a class="medical medical_review" href="/z/d/html/1292.html" rel="external">
          "Spinal epidural abscess", section on 'Management'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brain abscess (see
         <a class="medical medical_review" href="/z/d/html/1279.html" rel="external">
          "Treatment and prognosis of bacterial brain abscess"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H957222831">
         <span class="h2">
          Uncomplicated ABRS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Empiric therapy for children hospitalized with uncomplicated ABRS should provide activity against highly resistant
         <em>
          S. pneumoniae
         </em>
         , ampicillin-resistant
         <em>
          H. influenzae
         </em>
         , and ampicillin-resistant
         <em>
          M. catarrhalis
         </em>
         .
         <em>
         </em>
         The regimen should be adjusted based upon clinical response and culture results. (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
         We suggest initial empiric antibiotic therapy with one of the following agents  (
         <a class="graphic graphic_table graphicRef83454" href="/z/d/graphic/83454.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid32">
          32
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12695" href="/z/d/drug information/12695.html" rel="external">
          Ampicillin-sulbactam
         </a>
         200 to 400 mg/kg per day intravenously (IV) divided every six hours (maximum 8 g
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          ampicillin
         </a>
         component per day),
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          Ceftriaxone
         </a>
         50 mg/kg per day IV divided every 12 hours (maximum 4 g per day),
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          Levofloxacin
         </a>
         10 to 20 mg/kg per day IV divided every 12 to 24 hours (maximum 500 mg per day); levofloxacin should be reserved for cases in which there is no other safe and effective alternative [
         <a href="#rid58">
          58,60
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/490.html" rel="external">
          "Fluoroquinolones", section on 'Children'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         These suggestions are based on in vitro susceptibilities. There are no studies comparing intravenous antibiotic regimens for the treatment of ABRS in children.
        </p>
        <p>
         We continue antimicrobial therapy for a total of 10 days in patients whose symptoms improve after three days of parenteral therapy. We switch to oral antibiotics after the child shows definite signs of clinical improvement.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Positive sinus aspirate culture
         </strong>
         – For children with a positive sinus aspirate culture, we choose an oral agent to which the isolate is susceptible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Negative sinus aspirate culture or no sinus aspirate culture obtained
         </strong>
         – For children in whom sinus aspirate cultures were not obtained or were negative, the choice of oral therapy varies with the reason for admission:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those who were admitted because of failure to respond to initial oral therapy with
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         , we generally use either:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="13132" href="/z/d/drug information/13132.html" rel="external">
          Cefpodoxime
         </a>
         10 m/kg per day orally divided in two doses (maximum 400 mg/day),
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="13125" href="/z/d/drug information/13125.html" rel="external">
          Cefdinir
         </a>
         14 mg/kg per day orally divided in one or two doses (maximum 600 mg/day).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For children who improved with parenteral
         <a class="drug drug_pediatric" data-topicid="12695" href="/z/d/drug information/12695.html" rel="external">
          ampicillin-sulbactam
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         90 mg/kg per day of the
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         component orally in two divided doses (maximum daily dose 4 g) for 10 days; in the United States, the 600 mg amoxicillin/5 mL suspension or the 1000 mg extended-release tablet can be used for the appropriate clavulanate ratio.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          Levofloxacin
         </a>
         is an alternative but should be reserved for cases in which there is no other safe and effective alternative (eg, in patients who have anaphylaxis with or are intolerant of beta-lactams) [
         <a href="#rid58">
          58-60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those who were admitted because of toxic appearance, we usually switch to
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For children with no risk factors for resistance  (
         <a class="graphic graphic_table graphicRef122110" href="/z/d/graphic/122110.html" rel="external">
          table 5
         </a>
         ) –
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          Amoxicillin-clavulanate
         </a>
         45 mg/kg per day of the
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         component orally in two divided doses (maximum daily dose 1.75 g) for a total of 10 days.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For children with risk factors for resistance –
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          Amoxicillin-clavulanate
         </a>
         90 mg/kg per day of the
         <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">
          amoxicillin
         </a>
         component orally in two divided doses (maximum daily dose 4 g) for 10 days; in the United States, the 600 mg amoxicillin/5 mL suspension or the 1000 mg extended-release tablet can be used for the appropriate clavulanate ratio.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2304109787">
         <span class="h2">
          Treatment failure in inpatients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment failure is defined by substantial worsening at any time or failure to improve after three days of antimicrobial therapy [
         <a href="#rid39">
          39,40
         </a>
         ]. Causes of treatment failure in children with ABRS who are treated as inpatients include resistant pathogens, development of complications  (
         <a class="graphic graphic_table graphicRef83408" href="/z/d/graphic/83408.html" rel="external">
          table 3
         </a>
         ), noninfectious causes for symptoms, or ABRS as the initial presentation of immune deficiency [
         <a href="#rid32">
          32,38,61
         </a>
         ]. (See
         <a class="local">
          'Microbiology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6069.html" rel="external">
          "Acute bacterial rhinosinusitis in children: Clinical features and diagnosis", section on 'Differential diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5949.html" rel="external">
          "Approach to the child with recurrent infections"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional evaluation
         </strong>
         – Failure to improve or worsening in hospitalized children who are receiving empiric antibiotic therapy warrants additional evaluation, including [
         <a href="#rid32">
          32
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Consideration of noninfectious causes (eg, foreign body, structural abnormality) or ABRS as the initial presentation of immune deficiency [
         <a href="#rid32">
          32,38,61
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/6069.html" rel="external">
          "Acute bacterial rhinosinusitis in children: Clinical features and diagnosis", section on 'Differential diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5949.html" rel="external">
          "Approach to the child with recurrent infections"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Contrast-enhanced CT imaging or magnetic resonance imaging to exclude orbital and intracranial complications (if not performed previously)  (
         <a class="graphic graphic_table graphicRef83408" href="/z/d/graphic/83408.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Quantitative sinus aspirate cultures if they were not obtained at the time of admission (see
         <a class="medical medical_review" href="/z/d/html/6069.html" rel="external">
          "Acute bacterial rhinosinusitis in children: Clinical features and diagnosis", section on 'Microbiologic evaluation'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Changes to antibiotic therapy –
         </strong>
         For children with ABRS in whom other causes of symptoms have been excluded by history or examination, we modify initial antimicrobial therapy:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pathogen isolated from sinus aspirate
         </strong>
         – Antimicrobial therapy should be modified according to results of sinus aspirate culture as soon as the results are available.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          No pathogen isolated or cultures not performed
         </strong>
         – For children with ABRS who fail to improve despite parenteral therapy with
         <a class="drug drug_pediatric" data-topicid="12695" href="/z/d/drug information/12695.html" rel="external">
          ampicillin-sulbactam
         </a>
         , a third generation cephalosporin, or
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          levofloxacin
         </a>
         , and in whom no pathogen is isolated or sinus aspirate cultures are unavailable or contraindicated, the addition of
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         with or without
         <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">
          metronidazole
         </a>
         may be warranted [
         <a href="#rid75">
          75
         </a>
         ]. Vancomycin provides activity against highly resistant
         <em>
          S. pneumoniae
         </em>
         and
         <em>
          S. aureus
         </em>
         ; metronidazole provides activity against anaerobes.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          Vancomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">
          table 7
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">
          Metronidazole
         </a>
         30 mg/kg per day IV divided every six hours (maximum 4 g/day)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Response to escalated therapy
         </strong>
         – For patients who improve after changes to initial antimicrobial therapy, we continue antimicrobial therapy until they are free of symptoms for seven days (ie, a minimum of 10 days) [
         <a href="#rid38">
          38,62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who fail to respond to changes to escalated antimicrobial therapy, consultation with an infectious disease specialist and/or otolaryngologist is suggested.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3307256762">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109633.html" rel="external">
          "Society guideline links: Acute rhinosinusitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24597595">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/91181.html" rel="external">
          "Patient education: Sinusitis in children (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microbiology
         </strong>
         –
         <em>
          Haemophilus influenzae
         </em>
         (nontypeable),
         <em>
          Streptococcus pneumoniae,
         </em>
         and
         <em>
          Moraxella catarrhalis
         </em>
         are the predominant causes of uncomplicated acute bacterial rhinosinusitis (ABRS) in otherwise healthy children. (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outpatient management
         </strong>
         – We generally treat children with ABRS who are well-appearing and without complications or suspected complications  (
         <a class="graphic graphic_table graphicRef83408" href="/z/d/graphic/83408.html" rel="external">
          table 3
         </a>
         ) as outpatients. (See
         <a class="local">
          'Outpatient management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Empiric antibiotics
         </strong>
         – For children with uncomplicated ABRS  (
         <a class="graphic graphic_table graphicRef103739" href="/z/d/graphic/103739.html" rel="external">
          table 1
         </a>
         ), we suggest treatment with antimicrobial therapy rather than observation (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Improvement and resolution of symptoms are more likely with antibiotic therapy. (See
         <a class="local">
          'When to initiate antibiotics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Although we usually initiate antimicrobial therapy at the time of presentation, an alternative is to offer children with ABRS and 10 days of symptoms that are neither severe nor worsening the options of:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Empiric treatment after testing (performance of nasopharyngeal or nasal swab for presence of
         <em>
          H. influenzae
         </em>
         or
         <em>
          S. pneumoniae
         </em>
         ) with plan to discontinue if negative
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Testing with treatment only if test is positive
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Watchful waiting with treatment if symptoms persist beyond three days
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For initial treatment of uncomplicated ABRS in most children, we suggest
         <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">
          amoxicillin-clavulanate
         </a>
         rather than other oral antibiotics  (
         <a class="graphic graphic_algorithm graphicRef135260 graphicRef135256" href="/z/d/graphic/135260.html" rel="external">
          algorithm 1A-B
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). We prefer amoxicillin-clavulanate because of its spectrum of activity, effectiveness, and safety. (See
         <a class="local">
          'Empiric antibiotics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For children whose symptoms worsen substantially at any time or who fail to improve after three days of oral antibiotics, we broaden antimicrobial activity or switch to a different class  (
         <a class="graphic graphic_algorithm graphicRef135260 graphicRef135256" href="/z/d/graphic/135260.html" rel="external">
          algorithm 1A-B
         </a>
         and
         <a class="graphic graphic_table graphicRef83454" href="/z/d/graphic/83454.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="local">
          'Treatment failure in outpatients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Symptomatic management
         </strong>
         – For the management of nasal symptoms in children who do not have allergic rhinitis, we suggest topical
         <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">
          saline
         </a>
         rather than decongestants, antihistamines, or intranasal glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Although evidence of benefit is limited, topical saline is inexpensive and unlikely to be harmful. (See
         <a class="local">
          'Symptomatic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The treatment of allergic rhinitis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">
          "Pharmacotherapy of allergic rhinitis", section on 'Approach to specific patient groups'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inpatient management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Indications for hospitalization
         </strong>
         – Indications for hospitalization and parenteral therapy include (see
         <a class="local">
          'Indications for hospitalization'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Toxic appearance (lethargic, poorly perfused, cardiorespiratory compromise)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Complications or suspected complications  (
         <a class="graphic graphic_table graphicRef83408" href="/z/d/graphic/83408.html" rel="external">
          table 3
         </a>
         ); children older than one year with mild preseptal cellulitis are a possible exception
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Failure of outpatient therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Complicated ABRS
         </strong>
         – For children hospitalized with complicated ABRS  (
         <a class="graphic graphic_table graphicRef83408" href="/z/d/graphic/83408.html" rel="external">
          table 3
         </a>
         ), we perform sinus imaging with contrast-enhanced CT in patients with symptoms or signs of intracranial or orbital complications if imaging was not previously performed. Additional management varies depending upon the complication. It is discussed separately. (See
         <a class="local">
          'Complicated ABRS'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Uncomplicated ABRS
         </strong>
         – For children hospitalized with uncomplicated ABRS, we provide empiric therapy with activity against highly resistant
         <em>
          S. pneumoniae
         </em>
         , ampicillin-resistant
         <em>
          H. influenzae
         </em>
         , and ampicillin-resistant
         <em>
          M. catarrhalis
         </em>
         (
         <a class="graphic graphic_table graphicRef83454" href="/z/d/graphic/83454.html" rel="external">
          table 6
         </a>
         ). We adjust the regimen based upon culture results (if available) and clinical response. (See
         <a class="local">
          'Uncomplicated ABRS'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For children whose symptoms worsen substantially at any time or who fail to improve after three days of intravenous antibiotics, additional evaluation is warranted, including evaluation for complications and quantitative sinus aspirate cultures if these studies were not obtained at the time of admission. (See
         <a class="local">
          'Treatment failure in inpatients'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Gwaltney JM Jr, Scheld WM, Sande MA, Sydnor A. The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies. J Allergy Clin Immunol 1992; 90:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald ER. Microbiology of acute and chronic sinusitis in children and adults. Am J Med Sci 1998; 316:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parsons DS, Wald ER. Otitis media and sinusitis: similar diseases. Otolaryngol Clin North Am 1996; 29:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marchisio P, Ghisalberti E, Fusi M, et al. Paranasal sinuses and middle ear infections: what do they have in common? Pediatr Allergy Immunol 2007; 18 Suppl 18:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters AT, Spector S, Hsu J, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. Ann Allergy Asthma Immunol 2014; 113:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald ER, Milmoe GJ, Bowen A, et al. Acute maxillary sinusitis in children. N Engl J Med 1981; 304:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawada S, Matsubara S. Microbiology of Acute Maxillary Sinusitis in Children. Laryngoscope 2021; 131:E2705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pichichero ME. Otitis media. Pediatr Clin North Am 2013; 60:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Dongen TM, van der Heijden GJ, Venekamp RP, et al. A trial of treatment for acute otorrhea in children with tympanostomy tubes. N Engl J Med 2014; 370:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Dyke MK, Pirçon JY, Cohen R, et al. Etiology of Acute Otitis Media in Children Less Than 5 Years of Age: A Pooled Analysis of 10 Similarly Designed Observational Studies. Pediatr Infect Dis J 2017; 36:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaur R, Morris M, Pichichero ME. Epidemiology of Acute Otitis Media in the Postpneumococcal Conjugate Vaccine Era. Pediatrics 2017; 140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaur R, Fuji N, Pichichero ME. Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015-2019. Eur J Clin Microbiol Infect Dis 2022; 41:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald ER, DeMuri GP. Antibiotic Recommendations for Acute Otitis Media and Acute Bacterial Sinusitis: Conundrum No More. Pediatr Infect Dis J 2018; 37:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen R, Varon E, Doit C, et al. A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation. Vaccine 2015; 33:5118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Shimol S, Givon-Lavi N, Leibovitz E, et al. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV. Clin Infect Dis 2014; 59:1724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Shimol S, Givon-Lavi N, Leibovitz E, et al. Impact of Widespread Introduction of Pneumococcal Conjugate Vaccines on Pneumococcal and Nonpneumococcal Otitis Media. Clin Infect Dis 2016; 63:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitby CR, Kaplan SL, Mason EO Jr, et al. Staphylococcus aureus sinus infections in children. Int J Pediatr Otorhinolaryngol 2011; 75:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang WH, Hung PK. Methicillin-resistant Staphylococcus aureus infections in acute rhinosinusitis. Laryngoscope 2006; 116:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Payne SC, Benninger MS. Staphylococcus aureus is a major pathogen in acute bacterial rhinosinusitis: a meta-analysis. Clin Infect Dis 2007; 45:e121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald ER. Staphylococcus aureus: is it a pathogen of acute bacterial sinusitis in children and adults? Clin Infect Dis 2012; 54:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seltz LB, Smith J, Durairaj VD, et al. Microbiology and antibiotic management of orbital cellulitis. Pediatrics 2011; 127:e566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goytia VK, Giannoni CM, Edwards MS. Intraorbital and intracranial extension of sinusitis: comparative morbidity. J Pediatr 2011; 158:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster CE, Yarotsky E, Mason EO, et al. Molecular Characterization of Staphylococcus aureus Isolates From Children With Periorbital or Orbital Cellulitis. J Pediatric Infect Dis Soc 2018; 7:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulvey CL, Kiell EP, Rizzi MD, Buzi A. The Microbiology of Complicated Acute Sinusitis among Pediatric Patients: A Case Series. Otolaryngol Head Neck Surg 2019; 160:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brook I. Microbiology and choice of antimicrobial therapy for acute sinusitis complicated by subperiosteal abscess in children. Int J Pediatr Otorhinolaryngol 2016; 84:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miah MS, Nix P, Koukkoullis A, Sandoe J. Microbial causes of complicated acute bacterial rhinosinusitis and implications for empirical antimicrobial therapy. J Laryngol Otol 2016; 130:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coudert A, Ayari-Khalfallah S, Suy P, Truy E. Microbiology and antibiotic therapy of subperiosteal orbital abscess in children with acute ethmoiditis. Int J Pediatr Otorhinolaryngol 2018; 106:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peña MT, Preciado D, Orestes M, Choi S. Orbital complications of acute sinusitis: changes in the post-pneumococcal vaccine era. JAMA Otolaryngol Head Neck Surg 2013; 139:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otto WR, Paden WZ, Connors M, et al. Suppurative Intracranial Complications of Pediatric Sinusitis: A Single-Center Experience. J Pediatric Infect Dis Soc 2021; 10:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Troy E, Sillau S, Bernard TJ, Rao S. Incidence and Clinical Outcomes of Streptococcus anginosus in Acute Complicated Sinusitis: A Pediatric Cohort. J Pediatric Infect Dis Soc 2021; 10:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect 2009; 15 Suppl 3:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012; 54:e72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald ER, Mason EO Jr, Bradley JS, et al. Acute otitis media caused by Streptococcus pneumoniae in children's hospitals between 1994 and 1997. Pediatr Infect Dis J 2001; 20:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kellner JD, Ford-Jones EL. Streptococcus pneumoniae carriage in children attending 59 Canadian child care centers. Toronto Child Care Centre Study Group. Arch Pediatr Adolesc Med 1999; 153:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung A, Perera R, Brueggemann AB, et al. Effect of antibiotic prescribing on antibiotic resistance in individual children in primary care: prospective cohort study. BMJ 2007; 335:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald ER, Dashefsky B, Byers C, et al. Frequency and severity of infections in day care. J Pediatr 1988; 112:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messina NL, Williamson DA, Robins-Browne R, et al. Risk Factors for Carriage of Antibiotic-resistant Bacteria in Healthy Children in the Community: A Systematic Review. Pediatr Infect Dis J 2020; 39:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald ER, Applegate KE, Bordley C, et al. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. Pediatrics 2013; 132:e262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald ER, Chiponis D, Ledesma-Medina J. Comparative effectiveness of amoxicillin and amoxicillin-clavulanate potassium in acute paranasal sinus infections in children: a double-blind, placebo-controlled trial. Pediatrics 1986; 77:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald ER, Nash D, Eickhoff J. Effectiveness of amoxicillin/clavulanate potassium in the treatment of acute bacterial sinusitis in children. Pediatrics 2009; 124:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garbutt JM, Goldstein M, Gellman E, et al. A randomized, placebo-controlled trial of antimicrobial treatment for children with clinically diagnosed acute sinusitis. Pediatrics 2001; 107:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kristo A, Uhari M, Luotonen J, et al. Cefuroxime axetil versus placebo for children with acute respiratory infection and imaging evidence of sinusitis: a randomized, controlled trial. Acta Paediatr 2005; 94:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cronin MJ, Khan S, Saeed S. The role of antibiotics in the treatment of acute rhinosinusitis in children: a systematic review. Arch Dis Child 2013; 98:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaikh N, Hoberman A, Shope TR, et al. Identifying Children Likely to Benefit From Antibiotics for Acute Sinusitis: A Randomized Clinical Trial. JAMA 2023; 330:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blomgren K, Alho OP, Ertama L, et al. Acute sinusitis: Finnish clinical practice guidelines. Scand J Infect Dis 2005; 37:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manning SC. Pediatric sinusitis. Otolaryngol Clin North Am 1993; 26:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ip S, Fu L, Balk E, et al. Update on acute bacterial rhinosinusitis. Evid Rep Technol Assess (Summ) 2005; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2010; 29:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison CJ, Woods C, Stout G, et al. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother 2009; 63:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev 2007; 20:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Critchley IA, Brown SD, Traczewski MM, et al. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. Antimicrob Agents Chemother 2007; 51:4382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casey JR, Kaur R, Friedel VC, Pichichero ME. Acute otitis media otopathogens during 2008 to 2010 in Rochester, New York. Pediatr Infect Dis J 2013; 32:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savage TJ, Kronman MP, Sreedhara SK, et al. Treatment Failure and Adverse Events After Amoxicillin-Clavulanate vs Amoxicillin for Pediatric Acute Sinusitis. JAMA 2023; 330:1064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karageorgopoulos DE, Giannopoulou KP, Grammatikos AP, et al. Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. CMAJ 2008; 178:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeMuri GP, Wald ER. Clinical practice. Acute bacterial sinusitis in children. N Engl J Med 2012; 367:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arguedas A, Dagan R, Leibovitz E, et al. A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection. Pediatr Infect Dis J 2006; 25:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark C, Bozdogan B, Peric M, et al. In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin. Antimicrob Agents Chemother 2002; 46:2956.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm (Accessed on May 13, 2016).
         </li>
         <li class="breakAll">
          United States Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm (Accessed on July 28, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson MA, Schutze GE, COMMITTEE ON INFECTIOUS DISEASES. The Use of Systemic and Topical Fluoroquinolones. Pediatrics 2016; 138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro GG, Virant FS, Furukawa CT, et al. Immunologic defects in patients with refractory sinusitis. Pediatrics 1991; 87:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald ER. Sinusitis. Pediatr Ann 1998; 27:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaikh N, Wald ER. Decongestants, antihistamines and nasal irrigation for acute sinusitis in children. Cochrane Database Syst Rev 2014; :CD007909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallant JN, Basem JI, Turner JH, et al. Nasal saline irrigation in pediatric rhinosinusitis: A systematic review. Int J Pediatr Otorhinolaryngol 2018; 108:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang YH, Yang CP, Ku MS, et al. Efficacy of nasal irrigation in the treatment of acute sinusitis in children. Int J Pediatr Otorhinolaryngol 2009; 73:1696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoder JS, Straif-Bourgeois S, Roy SL, et al. Primary amebic meningoencephalitis deaths associated with sinus irrigation using contaminated tap water. Clin Infect Dis 2012; 55:e79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCormick DP, John SD, Swischuk LE, Uchida T. A double-blind, placebo-controlled trial of decongestant-antihistamine for the treatment of sinusitis in children. Clin Pediatr (Phila) 1996; 35:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patow CA, Kaliner M. Corticosteroid treatment of rhinologic diseases. Ear Nose Throat J 1983; 62:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barlan IB, Erkan E, Bakir M, et al. Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children. Ann Allergy Asthma Immunol 1997; 78:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meltzer EO, Orgel HA, Backhaus JW, et al. Intranasal flunisolide spray as an adjunct to oral antibiotic therapy for sinusitis. J Allergy Clin Immunol 1993; 92:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yilmaz G, Varan B, Yilmaz T, Gürakan B. Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children. Eur Arch Otorhinolaryngol 2000; 257:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zalmanovici Trestioreanu A, Yaphe J. Intranasal steroids for acute sinusitis. Cochrane Database Syst Rev 2013; :CD005149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald ER, Reilly JS, Casselbrant M, et al. Treatment of acute maxillary sinusitis in childhood: a comparative study of amoxicillin and cefaclor. J Pediatr 1984; 104:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordts F, Abu Nasser I, Clement PA, et al. Bacteriology of the middle meatus in children. Int J Pediatr Otorhinolaryngol 1999; 48:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald ER. Microbiology of acute and chronic sinusitis in children. J Allergy Clin Immunol 1992; 90:452.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5999 Version 48.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1527337" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9671039" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Microbiology of acute and chronic sinusitis in children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8834269" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Otitis media and sinusitis: similar diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17767605" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Paranasal sinuses and middle ear infections: what do they have in common?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25256029" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Diagnosis and management of rhinosinusitis: a practice parameter update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6970333" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Acute maxillary sinusitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33939189" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Microbiology of Acute Maxillary Sinusitis in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23481107" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Otitis media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24552319" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A trial of treatment for acute otorrhea in children with tympanostomy tubes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27918383" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Etiology of Acute Otitis Media in Children Less Than 5 Years of Age: A Pooled Analysis of 10 Similarly Designed Observational Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28784702" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Epidemiology of Acute Otitis Media in the Postpneumococcal Conjugate Vaccine Era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34432166" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29570583" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Antibiotic Recommendations for Acute Otitis Media and Acute Bacterial Sinusitis: Conundrum No More.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26271823" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25159581" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27225239" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Impact of Widespread Introduction of Pneumococcal Conjugate Vaccines on Pneumococcal and Nonpneumococcal Otitis Media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21074863" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Staphylococcus aureus sinus infections in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16467721" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Methicillin-resistant Staphylococcus aureus infections in acute rhinosinusitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17968816" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Staphylococcus aureus is a major pathogen in acute bacterial rhinosinusitis: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22198792" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Staphylococcus aureus: is it a pathogen of acute bacterial sinusitis in children and adults?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21321025" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Microbiology and antibiotic management of orbital cellulitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20970813" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Intraorbital and intracranial extension of sinusitis: comparative morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28575438" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Molecular Characterization of Staphylococcus aureus Isolates From Children With Periorbital or Orbital Cellulitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30481479" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The Microbiology of Complicated Acute Sinusitis among Pediatric Patients: A Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27063747" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Microbiology and choice of antimicrobial therapy for acute sinusitis complicated by subperiosteal abscess in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26678822" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Microbial causes of complicated acute bacterial rhinosinusitis and implications for empirical antimicrobial therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29447900" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Microbiology and antibiotic therapy of subperiosteal orbital abscess in children with acute ethmoiditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23429877" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Orbital complications of acute sinusitis: changes in the post-pneumococcal vaccine era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32955086" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Suppurative Intracranial Complications of Pediatric Sinusitis: A Single-Center Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31925948" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Incidence and Clinical Outcomes of Streptococcus anginosus in Acute Complicated Sinusitis: A Pediatric Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19366365" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22438350" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11176564" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Acute otitis media caused by Streptococcus pneumoniae in children's hospitals between 1994 and 1997.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10323630" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Streptococcus pneumoniae carriage in children attending 59 Canadian child care centers. Toronto Child Care Centre Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17656505" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effect of antibiotic prescribing on antibiotic resistance in individual children in primary care: prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3351677" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Frequency and severity of infections in day care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32301919" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Risk Factors for Carriage of Antibiotic-resistant Bacteria in Healthy Children in the Community: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23796742" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3520469" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Comparative effectiveness of amoxicillin and amoxicillin-clavulanate potassium in acute paranasal sinus infections in children: a double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19564277" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effectiveness of amoxicillin/clavulanate potassium in the treatment of acute bacterial sinusitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11335733" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A randomized, placebo-controlled trial of antimicrobial treatment for children with clinically diagnosed acute sinusitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16278986" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Cefuroxime axetil versus placebo for children with acute respiratory infection and imaging evidence of sinusitis: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23418037" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The role of antibiotics in the treatment of acute rhinosinusitis in children: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37490085" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Identifying Children Likely to Benefit From Antibiotics for Acute Sinusitis: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15871161" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Acute sinusitis: Finnish clinical practice guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8414531" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Pediatric sinusitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15989375" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Update on acute bacterial rhinosinusitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19935445" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19174454" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17428889" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Antimicrobial resistance in Haemophilus influenzae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17908940" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23860479" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Acute otitis media otopathogens during 2008 to 2010 in Rochester, New York.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37721610" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Treatment Failure and Adverse Events After Amoxicillin-Clavulanate vs Amoxicillin for Pediatric Acute Sinusitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18362380" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22992076" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Clinical practice. Acute bacterial sinusitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16511382" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12183253" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12183253" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12183253" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27940800" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The Use of Systemic and Topical Fluoroquinolones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2000270" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Immunologic defects in patients with refractory sinusitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9866138" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Sinusitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25347280" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Decongestants, antihistamines and nasal irrigation for acute sinusitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29605346" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Nasal saline irrigation in pediatric rhinosinusitis: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19786306" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Efficacy of nasal irrigation in the treatment of acute sinusitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22919000" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Primary amebic meningoencephalitis deaths associated with sinus irrigation using contaminated tap water.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8877243" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : A double-blind, placebo-controlled trial of decongestant-antihistamine for the treatment of sinusitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6832028" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Corticosteroid treatment of rhinologic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9207726" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8258615" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Intranasal flunisolide spray as an adjunct to oral antibiotic therapy for sinusitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10923938" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24293353" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Intranasal steroids for acute sinusitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6363660" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Treatment of acute maxillary sinusitis in childhood: a comparative study of amoxicillin and cefaclor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10375042" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Bacteriology of the middle meatus in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1527336" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Microbiology of acute and chronic sinusitis in children.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
